Experienced in Giant Cell Myocarditis

Stephane M. Oudard

Paris, FR 
Experienced in Giant Cell Myocarditis
Paris, FR 
OverviewLocationsClinical Research

Overview

Stephane Oudard practices in Paris, France. Ms. Oudard is rated as an Experienced expert by MediFind in the treatment of Giant Cell Myocarditis. Her top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Hemangioblastoma, Orchiectomy, and Nephrectomy.

Her clinical research consists of co-authoring 325 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Giant Cell Myocarditis.

Gender
Female

Locations

Paris, France
Other Locations
Georges, France
Creteil, France
INSERM UMR 1068, St. Quentin En Yvelines All In France, Saint-quentin-sur-indrois, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
Enrollment Status: Terminated
Publish Date: September 08, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Cisplatin, Carboplatin, Avelumab
Study Phase: Phase 2
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drug: Fuzuloparib+Abiraterone Acetate+Prednisone
Study Phase: Phase 3
CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With a Novel Hormonal Agent and Taxane-based Chemotherapy
CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With a Novel Hormonal Agent and Taxane-based Chemotherapy
Enrollment Status: Completed
Publish Date: June 25, 2024
Intervention Type: Drug
Study Drug: Abemaciclib
Study Phase: Phase 2
Everolimus Modulation of Anti-tumor T CD4 Immune Responses
Everolimus Modulation of Anti-tumor T CD4 Immune Responses
Enrollment Status: Terminated
Publish Date: May 16, 2022
Intervention Type: Other
Study Phase: Not Applicable
Randomized Multicenter, Phase III Trial Evaluating the Safety of 2 Schedules of Cabazitaxel (Bi-weekly Versus Tri-weekly) Plus Prednisone in Elderly Men (≥ 65years) With mCRPC Previously Treated With a Docetaxel-containing Regimen
Randomized Multicenter, Phase III Trial Evaluating the Safety of 2 Schedules of Cabazitaxel (Bi-weekly Versus Tri-weekly) Plus Prednisone in Elderly Men (≥ 65years) With mCRPC Previously Treated With a Docetaxel-containing Regimen
Enrollment Status: Completed
Publish Date: May 12, 2022
Intervention Type: Drug
Study Drugs: Cabazitaxel, Prednisone, Granulocyte colony-stimulating factor (G-CSF)
Study Phase: Phase 3
A First in Human Phase I Study of INVAC-1 as a Single Agent in Patients With Advanced Cancer
A First in Human Phase I Study of INVAC-1 as a Single Agent in Patients With Advanced Cancer
Enrollment Status: Completed
Publish Date: February 26, 2019
Intervention Type: Biological
Study Phase: Phase 1
View 6 Less Clinical Trials

325 Total Publications

Fake It till You Predict It: Data Augmentation Strategies to Detect Initiation and Termination of Oncology Treatment.
Fake It till You Predict It: Data Augmentation Strategies to Detect Initiation and Termination of Oncology Treatment.
Journal: Studies in health technology and informatics
Published: May 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Oudard's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 34 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile